Treatment for Atrial Fibrillation
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines the effectiveness of the Arctic Front™ cardiac cryoablation catheter system in treating paroxysmal atrial fibrillation (AF), a type of irregular heartbeat. The primary goal is to determine if this treatment can alleviate noticeable symptoms in individuals with AF. Ideal participants are those diagnosed with symptomatic paroxysmal AF who plan to undergo a procedure to isolate the pulmonary veins using this system. As a Phase 3 trial, it represents the final step before FDA approval, providing participants an opportunity to contribute to the potential availability of a new treatment option.
Why are researchers excited about this trial?
Most treatments for atrial fibrillation (AF) involve medications like beta-blockers or anti-arrhythmic drugs to manage heart rhythm. However, researchers are excited about the STOP AF First treatment because it utilizes a technique called cryoablation. Unlike traditional drug therapies, cryoablation targets the source of AF by freezing and destroying the problematic heart tissue that causes irregular rhythms. This approach can potentially offer long-term relief and reduce the need for ongoing medication. Additionally, cryoablation is minimally invasive, which can lead to quicker recovery times compared to other more invasive procedures.
Who Is on the Research Team?
Khaldoun Tarakji, MD
Principal Investigator
Medtronic CAS Chief Medical Officer
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are treated with the Arctic Front™ Cardiac Cryoablation Catheter System as an initial rhythm control strategy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medtronic Cardiac Ablation Solutions
Lead Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Lead Sponsor
Geoff Martha
Medtronic Cardiac Rhythm and Heart Failure
Chief Executive Officer since 2020
MBA from University of Minnesota
Dr. Kweli Thompson
Medtronic Cardiac Rhythm and Heart Failure
Chief Medical Officer since 2022
MD from Harvard Medical School
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.